Zelboraf

(Edi­tor’s Note: this is Part 1 of the new 3‑part series writ­ten by Dr. Evian Gor­don draw­ing from his par­tic­i­pa­tion at the Per­son­al­ized Med­i­cine World Con­gress on Jan­u­ary, 23, 2012 at Stan­ford University.)

On aver­age, the med­ica­tions pre­scribed for brain-relat­ed con­di­tions ben­e­fit approx­i­mate­ly 50% of patients. But which 50%?

Per­son­al­ized Med­i­cine seeks to move away from the cur­rent “1 size fits all, tri­al and error” approach that has been nec­es­sary because of a lack of evi­dence. Instead, it focus­es on [Read more…] about The State of Per­son­al­ized Med­i­cine: The Role of Biomarkers